European Journal of Internal Medicine
Volume 18, Issue 5 , Pages 423-429 , September 2007

Endogenous subclinical hyperthyroidism: Metabolic and cardiac parameters

  • T. Psaltopoulou

      Affiliations

    • Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Greece
    • Corresponding Author InformationCorresponding author. Kountouriotou 8, Cholargos, 15562, Athens, Greece. Tel.: +30 6944 506699.
    • ,
  • I. Ilias

      Affiliations

    • Endocrine Unit, Evgenidion Hospital, Greece
    • ,
  • S. Toumanidis

      Affiliations

    • Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Greece
    • ,
  • E. Mantzou

      Affiliations

    • Endocrine Unit, Evgenidion Hospital, Greece
    • ,
  • P. Marafellia

      Affiliations

    • Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Greece
    • ,
  • G. Piperingos

      Affiliations

    • Endocrine Unit, Evgenidion Hospital, Greece
    • ,
  • D.A. Koutras

      Affiliations

    • Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Greece
    • ,
  • M. Alevizaki

      Affiliations

    • Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Greece

Received 27 July 2006 ,Revised 27 November 2006 ,Accepted 15 December 2006.

References 

  1. Dimitriadis GD, Raptis SA. Thyroid hormone excess and glucose intolerance. Exp Clin Endocrinol Diabetes. 2001;109:S225–S239
  2. Dimitriadis G, Maratou E, Alevizaki M, et al. Thyroid hormone excess increases basal and insulin-stimulated recruitment of GLUT3 glucose transporters on cell surface. Horm Metab Res. 2005;37:15–20
  3. Faber J, Perrild H, Johansen J. Bone gla protein and sex-hormone-binding globulin in nontoxic goiter: parameters of metabolic status at the tissue level. J Clin Endocrinol Metab. 1990;70:49–55
  4. Kumeda Y, Inaba M, Tahara H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2000;85:4157–4161
  5. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501–509
  6. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol. 2005;152:1–9
  7. Biersack HJ, Hartmann F, Rodel R, Reinhardt M. Long term changes in serum T4, T3, and TSH in benign thyroid disease: proof of a narrow individual variation. Nuklearmedizin. 2004;43:158–160
  8. Hansen PS, Brix TH, Sorensen TI, Kyvik KO, Hegedus L. Major genetic influence on the regulation of the pituitary–thyroid axis: a study of healthy Danish twins. J Clin Endocrinol Metab. 2004;89:1181–1187
  9. Burmeister LA, Flores A. Subclinical thyrotoxicosis and the heart. Thyroid. 2002;12:495–499
  10. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993;77:334–338
  11. Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid. 1999;9:539–543
  12. Bauer DC, Nevitt MC, Ettinger B, Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab. 1997;82:2931–2936
  13. Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994;78:1028–1033
  14. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab. 1995;80:2222–2226
  15. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of l-thyroxine. J Clin Endocrinol Metab. 1997;82:2592–2595
  16. Petretta M, Bonaduce D, Spinelli L, et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145:691–696
  17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantifications in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083
  18. Lwanga SK, Lemeshow S. Sample size determination in health studies. Geneva: World Health Organization; 1991;
  19. Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol (Oxf). 1994;41:425–432
  20. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf). 1994;41:421–424
  21. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf). 1998;48:285–290
  22. Nystrom E, Lundberg PA, Petersen K, Bengtsson C, Lindstedt G. Evidence for a slow tissue adaptation to circulating thyroxine in patients with chronic l-thyroxine treatment. Clin Endocrinol (Oxf). 1989;31:143–150
  23. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease — scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228–238
  24. Lukert BP, Higgins JC, Stoskopf MM. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab. 1986;62:1056–1058
  25. Bambini G, Aghini-Lombardi F, Rosner W, et al. Serum sex hormone-binding globulin in amiodarone-treated patients. A marker for tissue thyrotoxicosis. Arch Intern Med. 1987;147:1781–1785
  26. Frevert EU, Biester A, Muller MJ, Schmidt-Gayk H, von zur Muhlen A, Brabant G. Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers. Eur J Endocrinol. 1994;131:145–149
  27. Alevizaki M, Mantzou E, Cimponeriu A, Alevizaki C, Koutras D. TSH may not be a good marker for adequate thyroid hormone replacement therapy. Wien Klin Wochenschr. 2005;117:636–640
  28. Campbell J, Day P, Diamond T. Fine adjustments in thyroxine replacement and its effect on bone metabolism. Thyroid. 1996;6:75–78
  29. Loviselli A, Mastinu R, Rizzolo E, et al. Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid. 1997;7:561–566
  30. Ross DS, Ardisson LJ, Nussbaum SR, Meskell MJ. Serum osteocalcin in patients taking l-thyroxine who have subclinical hyperthyroidism. J Clin Endocrinol Metab. 1991;72:507–509
  31. Faber J, Gailloe AM. Changes of bone mass during prolonged subclinical hyperthyroidism due to l-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994;130:350–356
  32. Uzzan B, Campos J, Cucherat M, Novy P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 1996;48:285–290
  33. Tauchmanova L, Nuzzo V, Del Puente A, et al. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas. 2004;48:299–306
  34. Loviselli A, Rizzolo E, Mastinu R, et al. High serum circulating telopeptide type I in multinodular goiter. Horm Metab Res. 2003;35:377–381
  35. Brenta G, Schnitman M, Gurfinkiel M, et al. Variations of sex hormone-binding globulin in thyroid dysfunction. Thyroid. 1999;9:273–277
  36. Sgarbi JA, Villaca F, Garbeline B, Villar HE, Romaldini J. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism on clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88:1672–1677
  37. Boutin JM, Matte R, D'Amour P, et al. Characteristics of patients with normal T3 and T4 and a low TSH response to TRH. Clin Endocrinol (Oxf). 1986;25:579–588
  38. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145:391–396
  39. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85:4701–4705

PII: S0953-6205(07)00128-8

doi: 10.1016/j.ejim.2006.12.010

European Journal of Internal Medicine
Volume 18, Issue 5 , Pages 423-429 , September 2007

Article Tools